CDX2 anticorps (AA 1-30)

N° du produit ABIN3030336

Détail du produit anti-CDX2 anticorps

Antigène: CDX2 (Caudal Type Homeobox 2 (CDX2))

Épitope: AA 1-30

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CDX2 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Réactivité croisée (Details): Expected species reactivity: Mouse

Purification: Purified

Immunogène: A portion of amino acids 1-30 from the human protein was used as the immunogen for this CDX2 antibody.

Isotype: Ig Fraction

Information d'application

Indications d'application: Titration of the CDX2 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000,IHC (Paraffin): 1:50-1:100

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Aliquot the CDX2 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Détails sur CDX2

Antigène: CDX2 (Caudal Type Homeobox 2 (CDX2))

Autre désignation: CDX2 (CDX2 Produits)

Synonymes: anticorps CDX2, anticorps MGC130987, anticorps cdx3-like, anticorps CDX-3, anticorps CDX3, anticorps CDX-2, anticorps Cdx-2, anticorps caudal type homeobox 2, anticorps caudal type homeobox 2 L homeolog, anticorps caudal type homeo box 2, anticorps CDX2, anticorps cdx2.L, anticorps Cdx2

Sujet: The caudal type homeo box transcription factors 1 (CDX1) and 2 (CDX2) are candidates for directing intestinal development, differentiation, and maintenance of the intestinal phenotype. CDX1 and CDX2 expression is widely present in the human intestinal and colonic mucosae, but not in the gastric mucosa, suggesting a possible role in the terminal differentiation of the intestine. Increased CDX2 expression is associated with chronic atrophic gastritis. Detectable expression of CDX2 precedes expression of CDX1 during the progression of intestinal metaplasia, thus expression of CDX2 may trigger the initiation and development of intestinal metaplasia. Markedly reduced or absent CDX2 expression was noted by immunohistochemistry in 13 of 15 (87 % ) large cell minimally differentiated carcinomas (LCMDCs), whereas only 1 of the 25 (4 %) differentiated adenocarcinomas (DACs) showed reduced CDX2 expression. Thus, a significant decrease in human CDX1 and/or CDX2 expression may be associated with colorectal tumorigenesis.

UniProt: Q99626

Pathways: Peptide Hormone Metabolism, Stem Cell Maintenance